Suboptimal molecular response to tyrosine kinase inhibition associated with acquisition of a T240A ABL1 kinase domain mutation in a patient with chronic myeloid leukemia
Over the last twenty years, chronic myeloid leukemia (CML) has come to be considered a paradigm for rationally selected, targeted inhibition of the disease-specific, BCR-ABL1 tyrosine kinase activity. However, a minor but significant numbers of patients either fail, or have suboptimal respo...
Saved in:
| Date: | 2023 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Published: |
PH Akademperiodyka
2023
|
| Subjects: | |
| Online Access: | https://exp-oncology.com.ua/index.php/Exp/article/view/2019-1-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Journal Title: | Experimental Oncology |